IP Watchdog

DECEMBER 21, 2021

In this post (Part I), we provide a 2021 year in review update on mRNA pioneers Moderna, BioNTech and CureVac, and in Part II, we profile Sanofi and other companies in the mRNA space and offer additional conclusions and outlook for 2022 and beyond.

IP 124

IP Marketing Marketing Business 124

JD Supra Law

NOVEMBER 11, 2022

Supreme Court has agreed to hear a case that is extremely significant for companies that operate in the biotechnology, pharmaceutical, and chemical sectors. At issue in Amgen v.

Invention 98

Invention Art Government Patent 98

JD Supra Law

SEPTEMBER 14, 2023

Sanofi, 987 F.3d The Court thus left in place a significant CAFC decision making it more difficult for drug companies to block competitive products in the United States that are functionally equivalent, but structurally different. 3d 1080 (CA Fed.

Patent 64

Patent 64

Herbert Smith Freehills

AUGUST 18, 2022

Leading international law firm Herbert Smith Freehills has advised innovative global healthcare company Sanofi on its €300 million strategic equity investment in Chinese biopharmaceutical company Innovent Biologics.

Marketing 52

Marketing Marketing Technology Publishing 52

Managing IP

DECEMBER 8, 2021

Six months after US v Arthrex, counsel at Thermo Fisher, Sanofi and two other companies set out how they plan to use the USPTO's director review process

90

90

IPilogue

FEBRUARY 13, 2023

On November 4th, 2022, the Supreme Court granted certiorari to review the Federal Circuit’s decision in Amgen v Sanofi , against the recommendation of the US government. In 2014, Amgen sued Sanofi for infringing on its patents concerning drugs for lowering cholesterol.

Patent 101

Patent Invention Art Inventor 101

IP Watchdog

DECEMBER 27, 2021

In this post we profile Sanofi, Arcturus, eTheRNA and other mRNA companies and offer conclusions. Sanofi (NASDAQ: SNY), headquartered in Paris, FR, acquired mRNA pioneer Translate Bio in September 2021 for approximately $3.2 billion and mRNA startup Tidal Therapeutics in April 2021 for approximately $470 million.

IP 64

IP Patent Licensing Technology 64

JD Supra Law

JULY 21, 2023

Amgen) a biopharmaceutical company, had developed cholesterol-lowering antibody drugs, and obtained two patents. Supreme Court recently struck down broad patent claims covering a “genus” of antibodies, reaffirming in a 9-0 decision that a patent must “enable” the full scope of its claims (Amgen Inc. Amgen, Inc., By: Smith Anderson

Patent 52

Patent 52

JD Supra Law

JUNE 7, 2023

Sanofi, 987 F.3d The Court thus left in place a significant decision making it more difficult for drug companies to block competitive products that are functionally equivalent, but structurally different. On May 18, 2023, the Supreme Court affirmed the Federal Circuit’s (CAFC) decision on enablement in Amgen Inc. 3d 1080 (CA Fed.

Patent 55

Patent 55

McKinsey Operations

JANUARY 11, 2023

In the wake of the COVID-19 pandemic, one of the first non-French leaders of the pharmaceutical company Sanofi explains cultural transformations, the growth of AI in decision making, and how he stays humble.

62

62

Herbert Smith Freehills

JULY 5, 2022

Sanofi made an investment of US$15 million into ClouDr as a cornerstone investor in its global offering. "We We are delighted to have advised Sanofi on this landmark transaction," said Kewei international partner Gavin Guo.

Marketing 52

Marketing Marketing Technology Publishing 52

IP Watchdog

JANUARY 13, 2022

In this post we profile Sanofi, Arcturus, eTheRNA and other mRNA companies and offer conclusions. Sanofi (NASDAQ: SNY), headquartered in Paris, FR, acquired mRNA pioneer Translate Bio in September 2021 for approximately $3.2 billion and mRNA startup Tidal Therapeutics in April 2021 for approximately $470 million.

IP 59

IP Publishing Patent Licensing 59

IP Law 360

NOVEMBER 22, 2021

subsidiary of the French multinational pharmaceutical corporation Sanofi SA has agreed to pay $180 million to resolve a dispute with a Taiwanese company over patents aimed at treating a rare neuromuscular disease, ending ongoing arbitrations over royalties.

Patent 75

Patent 75

Managing IP

DECEMBER 1, 2021

In part two of our generalist-specialist series, counsel at five companies including Sanofi say it’s vital for litigation teams to have deep experts and all-rounders

Litigation 59

Litigation Patent 59

Managing IP

APRIL 14, 2022

Companies in IP-intensive acquisitions must contend with freedom to operate and licences, say counsel at Siemens, Sanofi, USG and two law firms

IP 52

IP Law 52

Managing IP

OCTOBER 28, 2021

In-house counsel at Sanofi and two tech companies reveal how they manage these proceedings and what private practice lawyers can do to help

52

52

IP Law 360

FEBRUARY 13, 2023

The federal government, various drug companies and a molecular biologist who won the Nobel Prize for his work with monoclonal antibodies urged the U.S. Supreme Court to keep the standard of patent enablement as is, backing Sanofi and Regeneron in their fight against Amgen.

Government 40

Government IP Patent 40

IP Law 360

SEPTEMBER 14, 2022

A Puerto Rico subsidiary of Sanofi-Aventis cannot be held liable for any alleged antitrust violations by its parent company in a suit accusing the pharmaceutical giant of improperly listing patents for the injector pen of lucrative diabetes drug Lantus, a Boston federal judge ruled Wednesday.

Patent 40

Patent 40

Managing IP

JUNE 28, 2021

Five in-house counsel from Sanofi, USG and other companies reveal how to sway the board to deny IPR institution

Patent 52

Patent 52

LexBlog IP

OCTOBER 18, 2023

The agreement grants Meitheal and its parent company, Nanjing King-Friend Biochemical Pharmaceutical Co., To date, there are two FDA-approved biosimilars to Sanofi’s LANTUS (insulin glargine): Eli Lilly’s REZVOGLAR (insulin glargine-aglr) and Mylan’s SEMGLEE (insulin glargine-yfgn).

Licensing 52

Licensing Marketing Marketing Intellectual Property 52

LexBlog IP

MAY 31, 2023

Sanofi – involves a dispute between the two pharmaceutical companies over the “enablement” requirement of 35 U.S.C. Sanofi et al. Supreme Court invalidated two of Amgen’s patents for its cholesterol drug, Repatha, making it more difficult for patentees to obtain broadly worded patents. [1]

Invention 52

Invention Art Inventor Patent 52

LexBlog IP

DECEMBER 23, 2021

On Monday the FDA approved Eli Lilly’s insulin glargine biosimilar Rezvoglar, a biosimilar to Sanofi’s Lantus. Lannett Company, Inc. Lannett is co-developing the product with partners within the HEC Group of companies. Rezvoglar is available in 3 mL prefilled pens and is administered subcutaneously once daily.

Licensing 52

Licensing Intellectual Property 52

43(B)log

OCTOBER 6, 2021

Plaintiff Sanofi failed to show a triable issue of fact on (1), (5), and (6). Likewise, statements about why payors didn’t include Sanofi’s product in their formularies weren’t clearly false despite Sanofi’s argument that they misleadingly implied that there were safety concerns. The latter were also nonactionable opinion.

False Advertising 45

False Advertising Advertising Advertising Marketing 45

Patently-O

MAY 1, 2023

A skinny-label occurs when a generic drug company seeks approval for a drug with a label that omits the patented indications of the brand-name drug. Sanofi case, argued in March 2023. GlaxoSmithKline LLC , No. Polar Electro Oy , No. In addition, the Supreme Court has yet to rule on the Amgen v.

Patent 80

Patent Technology Patent Infringement Branding 80

LexBlog IP

DECEMBER 27, 2021

In February, the Federal Circuit affirmed a decision invalidating two Amgen patents that were alleged to cover Amgen’s cholesterol-lowering drug Repatha® (evolocumab) and Sanofi’s Praluent® (alirocumab). billion jury verdict in favor of the patent owner.

Litigation 52

Litigation Intellectual Property Patent Contracts 52

Patently-O

APRIL 21, 2022

Sanofi, et al., Becton, Dickinson and Company , No. Scope and Procedure for the Enablement Requirement: Amgen Inc., 21-757 (CVSG requested April 18, 2022); Infringement and Damages: Do Enhanced Damages Require “Egregious Behavior” : Cisco Systems, Inc. SRI International, Inc. ,

Patent Law 82

Patent Law Law Patent Art 82

43(B)log

MARCH 20, 2023

15, 2023) The state sued two pharmaceutical companies for violating Hawai‘i’s Unfair or Deceptive Acts or Practices law (UDAP) by misleading the public about the safety and efficacy of their antiplatelet drug, Plavix. State ex rel. Bristol-Myers Squibb Co., 2023 WL 2519857, SCAP-21-0000363, P.3d 3d - (Hawai’i Mar.

Law 45

Law Advertising Advertising Journalism 45

Patently-O

NOVEMBER 29, 2023

23-491 This case arises from multiple patent infringement lawsuits filed by Realtime Data LLC (d/b/a IXO) against various technology companies, including Fortinet, Inc., Sanofi, 142 S. Fortinet, No. Reduxio Systems, Inc., and others in the District of Delaware. 101 as claiming only abstract ideas and no inventive concept. 1713 (2022).

Patent Law 73

Patent Law Law Patent Art 73

Bio Law Blog

APRIL 15, 2020

After Genentech ’s tocilizumab (Actemra), an IL-6R inhibitor, was tested on patients in a Chinese trial and showed promising results, Regeneron and Sanofi began testing their own IL-6R inhibitor, sarilumab (Kevzara), and EUSA Pharma began trials with its IL-6 inhibitor, siltuximab (Sylvant).

Copying 40

Copying Designs Design 40

Patently-O

FEBRUARY 24, 2022

Sanofi has the potential of being a huge case in terms of how it impacts the future of biotech innovation. .” And, rather than basing its argument on the 7th Amendment, Daikin’s petition is grounded in the Administrative Procedure Act and “the principles of separation of powers embedded within that Act.”

Patent Law 95

Patent Law Law Patent Litigation 95

SpicyIP

DECEMBER 4, 2023

Sanofi India Limited vs Saint Michael Biotech & Ors on 24 November, 2023 (Delhi High Court) Holding the defendant’s marks “Comflam/ Comflam+” deceptively similar to the plaintiff’s “Combiflam” mark, the court passed an ad interim injunction, restraining the defendant from using the impugned marks.

Registration 59

Registration Artistic Work Technology Patent 59

Fish & Richardson Trademark & Copyright Thoughts

FEBRUARY 4, 2021

As of the March 23, 2020 transition, however, all “biological product” applications previously approved under the FD&C Act were “deemed” approved under the PHS Act, and companies can now seek biosimilars and interchangeables of these biological products. As noted above, companies are already taking advantage of these new designations.

Settlement 52

Settlement Litigation Marketing Marketing 52

SpicyIP

MARCH 27, 2023

The petitioner is a music company and claims to own copyright of the singer’s songs which were allegedly being streamed by the defendant. Other IP developments Spotify removes Zee Music company’s catalog, including most streamed songs in a licensing dispute.

Designs 105

Designs Design Cease and Desist Art 105

The IPKat

SEPTEMBER 23, 2021

Inequitable conduct includes, for example, intentionally failing to disclose information to the USPTO that is material to the patentability of an application (see also Sanofi-Aventis v Hospira , IPKat ). adrenaline formulation into the market. Belcher even performed stability tests on this formulation, and found it to be stable.

Patent Prosecution 57

Patent Prosecution Patent Patent Application Art 57

LexBlog IP

OCTOBER 19, 2021

Eli Lilly and Company , Appeals 2020-1747, -1748, and -1750 (Fed. Sanofi, Aventisub LLC , 987 F.3d In Teva Pharmaceuticals Int’l GmbH v. 16, 2021), the Federal Circuit again dealt with patents broadly claiming antibodies. But here the court confronted Patent Trial and Appeal Board decisions that canceled patent claims as obvious.

Invention 52

Invention Licensing Art Patent 52

SpicyIP

DECEMBER 12, 2022

The Petitioner filed a writ petition against the order passed by Regional Director, Ministry of Corporate Affairs, under Section 22 of Companies Act, directing it to change its name from ‘Raymond Pharmaceuticals’. GSK, Pfizer and Sanofi find relief as US court says Zantac-linked cancer not ‘backed by science’. Image from here.

Copyright Infringement 105

Copyright Infringement Settlement Registration Trademark 105

Fish & Richardson Trademark & Copyright Thoughts

JANUARY 11, 2022

Several other companies have also announced plans to pursue interchangeable status for biosimilar products. Consistent with this, as shown below in Table 2, numerous companies have publicly announced the submission and/or acceptance of new biosimilar BLAs. No earlier than 2023 per settlement. Rezvoglar ™. Eli Lilly). December 17, 2021.

Litigation 52

Litigation Settlement Patent Marketing 52